Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 61

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Liradasertib
  • Sponsor:Biogen Idec Research Limited

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Asciminib and Asciminib Hydrochloride for Patients with Chronic Myelogenous Leukemia in Chronic Phase After Two or More Tyrosine Kinase Inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib
  • Sponsor:Novartis Pharma AG

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:Astrazeneca AB

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Treprostinil Palmitil Inhalation Powder for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.